BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. to Present at the Rodman

[Biostar Pharmaceuticals, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 12:30 pm ET XIANYANG, China, Sep. 7 - Biostar Pharmaceuticals, Inc. (Nasdaq:BSPM) ("Biostar" or "the Company"), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing Capsules"), and a variety of pharmaceutical products, today announced that]

By | 2016-03-03T14:06:22+00:00 September 7th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, to Present at the Rodman & Renshaw Annual Global Investmentnference on September 13 at 12:30 pm ET XIANYANG, China, Sep. 7 - Biostar Pharmaceuticals, (Nasdaq:BSPM) ("Biostar" or "thempany"), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acidpsules ("Xin Aoxingpsules"), and a variety of pharmaceutical products, today announced that it]

By | 2016-02-07T16:52:43+00:00 September 7th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, to Present at the Rodman &

[Biostar Pharmaceuticals, to Present at the Rodman & Renshaw Annual Global Investmentnference on September 13 at 12:30 pm ET XIANYANG, China, Sep. 7 - Biostar Pharmaceuticals, (Nasdaq:BSPM) ("Biostar" or "thempany"), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acidpsules ("Xin Aoxingpsules"), and a variety of pharmaceutical products, today announced that it]

By | 2016-02-07T16:53:18+00:00 September 7th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, INC. SECOND QUARTER REVENUE INCREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 - Q2 2010 revenue increased 46.4% to $19.4 million - Q2 2010 Non-GAAP adjusted net income increased 50.9% to $5.8 million with adjusted EPS of $0.21 - Biostar reiterates guidance for 2010: Revenue expected to be between $80.0 to $82.0 million and net income]

By | 2016-03-03T14:09:01+00:00 August 17th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, INC. SECOND QUARTER REVENUE INCREASED 46.4%

[BIOSTAR PHARMACEUTICALS, INC. SECOND QUARTER REVENUE INCREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 - Q2 2010 revenue increased 46.4% to $19.4 million - Q2 2010 Non-GAAP adjusted net income increased 50.9% to $5.8 million with adjusted EPS of $0.21 - Biostar reiterates guidance for 2010: Revenue expected to be between $80.0 to $82.0 million and net income]

By | 2016-03-03T14:10:24+00:00 August 17th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, SECOND QUARTER REVENUEREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 - Q2 2010 revenuereased 46.4% to $19.4 million - Q2 2010 Non-GAAPjusted netomereased 50.9% to $5.8 million withjusted EPS of $0.21 - Biostar reiterates guidance for 2010: Revenue expected to be between $80.0 to $82.0 million and netome between $18.0 to]

By | 2016-02-07T16:54:40+00:00 August 17th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, SECOND QUARTER REVENUEREASED 46.4% TO $19.4

[BIOSTAR PHARMACEUTICALS, SECOND QUARTER REVENUEREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 - Q2 2010 revenuereased 46.4% to $19.4 million - Q2 2010 Non-GAAPjusted netomereased 50.9% to $5.8 million withjusted EPS of $0.21 - Biostar reiterates guidance for 2010: Revenue expected to be between $80.0 to $82.0 million and netome between $18.0 to]

By | 2016-02-07T16:55:13+00:00 August 17th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2010 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [LABOR CONTRACT Party A: Shaanxi Aoxing Pharmaceutical Co., Ltd. Address: Chenyangzhai, Xianyang Legal Representative: Ronghua Wang Party B: Ronghua Wang Address: Shenjia Xiaoqu, Floor 21, Room 3103, Qindu District, Xiayang ID number: xxxxxxxxxxxxxxx Parties Party A and Party B (the “ I. Term of Employment 1. Agreement Part A agrees to employ Party B and enter into this labor contract] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Deyin Chen, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Deyin Chen Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]

By | 2016-03-03T14:12:09+00:00 August 13th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x June 30, 2010

[FORM 10-Q (Mark One) x June 30, 2010 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [LABOR CONTRACT Party A: Shaanxi Aoxing Pharmaceutical Co., Ltd. Address: Chenyangzhai, Xianyang Legal Representative: Ronghua Wang Party B: Ronghua Wang Address: Shenjia Xiaoqu, Floor 21, Room 3103, Qindu District, Xiayang ID number: xxxxxxxxxxxxxxx Parties Party A and Party B (the “ I. Term of Employment 1. Agreement Part A agrees to employ Party B and enter into this labor contract] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Deyin Chen, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Deyin Chen Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]

By | 2016-03-03T14:13:12+00:00 August 13th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2010 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [LABORNTRACT Party A: Shaanxi Aoxing Pharmaceuticaldress: Chenyangzhai, Xianyang Legal Representative: Ronghua Wang Party B: Ronghua Wangdress: Shenjia Xiaoqu, Floor 21, Room 3103, Qindu District, Xiayang ID number: xxxxxxxxxxxxxxx Parties Party A and Party B (the I. Term of Employment 1.reement Part Arees to employ Party B and enter into this laborntract (the] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Deyin Chen, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Deyin Chen Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 6 EX-32.2]

By | 2016-02-07T17:17:17+00:00 August 13th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar